Repligen (NASDAQ:RGEN) Shares Gap Down – Time to Sell?

Shares of Repligen Co. (NASDAQ:RGEN) gapped down prior to trading on Tuesday . The stock had previously closed at $152.81, but opened at $144.61. Repligen shares last traded at $144.27, with a volume of 140,346 shares trading hands.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. TD Cowen assumed coverage on Repligen in a report on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective on the stock. Royal Bank of Canada raised their price objective on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. Evercore ISI began coverage on Repligen in a report on Tuesday. They set an “in-line” rating and a $155.00 price target on the stock. Canaccord Genuity Group began coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $180.00 price target on shares of Repligen in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Repligen presently has a consensus rating of “Hold” and an average target price of $178.64.

Repligen Stock Performance

The stock has a market capitalization of $8.12 billion, a PE ratio of -284.08, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The firm’s fifty day moving average is $156.78 and its 200-day moving average is $148.46. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. As a group, research analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current year.

Insiders Place Their Bets

In other Repligen news, Director Margaret Pax purchased 250 shares of the business’s stock in a transaction on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

A number of institutional investors and hedge funds have recently bought and sold shares of RGEN. Atria Investments Inc increased its stake in Repligen by 67.9% during the third quarter. Atria Investments Inc now owns 3,202 shares of the biotechnology company’s stock worth $477,000 after purchasing an additional 1,295 shares during the period. CIBC Asset Management Inc purchased a new stake in shares of Repligen during the third quarter worth approximately $242,000. Natixis Advisors LLC increased its stake in shares of Repligen by 53.6% during the third quarter. Natixis Advisors LLC now owns 33,625 shares of the biotechnology company’s stock worth $5,004,000 after buying an additional 11,731 shares during the period. Quest Partners LLC purchased a new stake in shares of Repligen during the third quarter worth approximately $166,000. Finally, Pathstone Holdings LLC increased its stake in shares of Repligen by 32.4% during the third quarter. Pathstone Holdings LLC now owns 22,284 shares of the biotechnology company’s stock worth $3,316,000 after buying an additional 5,459 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.